IntelliGender release raises abortion fears
By Courier Mail,
Courier Mail
| 05. 10. 2009
A test that claims to determine the sex of an unborn baby only eight weeks into a pregnancy will be available in pharmacies from today.
IntelliGender, the first test of its kind in Australia, claims a 90 per cent accuracy rate in determining whether a baby will be a boy or a girl.
Doctors and the anti-abortion lobby, however, fear the test will be used as a means of sex selection and drive up abortion rates.
The company behind the $95 test, which has been sold in the US since 2006, says it takes 10 minutes and identifies a "confidential element" found in the hormones of a woman pregnant with a girl.
The element is found in very low levels in women pregnant with a boy or not pregnant at all.
Currently, women who want to find out their baby's gender can do so at a routine 18- to 20-week ultrasound to check on the health and development of the child.
Royal Australian and New Zealand College of Obstetricians and Gynaecologists president Dr Ted Weaver said there appeared to be...
Related Articles
By Grace Won, KQED [with CGS' Katie Hasson] | 12.02.2025
In the U.S., it’s illegal to edit genes in human embryos with the intention of creating a genetically engineered baby. But according to the Wall Street Journal, Bay Area startups are focused on just that. It wouldn’t be the first...
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...
By Antonio Regalado, MIT Technology Review | 10.31.2025
A West Coast biotech entrepreneur says he’s secured $30 million to form a public-benefit company to study how to safely create genetically edited babies, marking the largest known investment into the taboo technology.
The new company, called Preventive, is...
